Bexlosteride

Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer[1][2].

Product Specifications

CAS Number

[148905-78-6]

Product Name Alternative

LY300502

UNSPSC

12352005

Target

5 alpha Reductase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bexlosteride.html

Solubility

10 mM in DMSO

Smiles

CN1[C@@]2([H])[C@@](CCC1=O)([H])C3=CC=C(Cl)C=C3CC2

Molecular Formula

C14H16ClNO

Molecular Weight

249.74

References & Citations

[1]Sutkowski DM, et, al. Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor. Prostate Suppl. 1996;6:62-6.|[2]Farid NA, et, al. Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs. Drug Metab Dispos. 1996 Oct;24 (10) :1162-5.